HAE Stock - Haemonetics Corporation
Unlock GoAI Insights for HAE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.36B | $1.31B | $1.17B | $993.20M | $870.46M |
| Gross Profit | $778.55M | $711.91M | $622.87M | $530.77M | $428.45M |
| Gross Margin | 57.2% | 54.4% | 53.3% | 53.4% | 49.2% |
| Operating Income | $221.82M | $164.88M | $156.03M | $80.75M | $89.75M |
| Net Income | $167.68M | $117.56M | $115.40M | $43.38M | $79.47M |
| Net Margin | 12.3% | 9.0% | 9.9% | 4.4% | 9.1% |
| EPS | $3.31 | $2.32 | $2.27 | $0.85 | $1.57 |
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | Needham | Downgrade | Hold | - |
| December 11th 2025 | Citigroup | Downgrade | Neutral | $88 |
| August 11th 2025 | Raymond James | Downgrade | Outperform | $78 |
| August 8th 2025 | Barrington Research | Reiterated | Outperform | $86← $95 |
| August 8th 2025 | JP Morgan | Downgrade | Neutral | $62 |
| July 9th 2025 | Citigroup | Upgrade | Buy | $90 |
| June 26th 2025 | Robert W. Baird | Initiation | Outperform | $87 |
| February 7th 2025 | BofA Securities | Downgrade | Underperform | $68← $95 |
| December 6th 2024 | JP Morgan | Initiation | Overweight | $116 |
| November 8th 2024 | Raymond James | Upgrade | Strong Buy | $120 |
| September 13th 2024 | CL King | Initiation | Buy | $116 |
| September 11th 2024 | BofA Securities | Initiation | Neutral | $85 |
| September 10th 2024 | BTIG Research | Initiation | Buy | $112 |
| June 12th 2024 | Needham | Upgrade | Buy | $112 |
| October 13th 2022 | Mizuho | Initiation | Buy | $90 |
Earnings History & Surprises
HAEEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $1.27 | — | — | — |
Q4 2025 | Nov 6, 2025 | $1.12 | $1.27 | +13.4% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $1.01 | $1.10 | +8.9% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $1.22 | $1.24 | +1.6% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $1.18 | $1.19 | +0.8% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $1.09 | $1.12 | +2.8% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $1.03 | $1.02 | -1.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $0.88 | $0.90 | +2.3% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $0.97 | $1.04 | +7.2% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.94 | $0.99 | +5.3% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $0.73 | $1.05 | +43.8% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $0.68 | $0.77 | +13.2% | ✓ BEAT |
Q1 2023 | Feb 7, 2023 | $0.79 | $0.85 | +7.6% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $0.67 | $0.83 | +23.9% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $0.53 | $0.58 | +9.4% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $0.60 | $0.65 | +8.3% | ✓ BEAT |
Q1 2022 | Feb 8, 2022 | $0.75 | $0.84 | +12.0% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $0.63 | $0.60 | -4.8% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $0.47 | $0.50 | +6.4% | ✓ BEAT |
Latest News
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $90
📈 PositiveBaird Maintains Outperform on Haemonetics, Raises Price Target to $99
📈 PositiveNeedham Downgrades Haemonetics to Hold
📉 NegativeJP Morgan Maintains Neutral on Haemonetics, Raises Price Target to $74
➖ NeutralCitigroup Downgrades Haemonetics to Neutral, Raises Price Target to $88
➖ NeutralBTIG Reiterates Buy on Haemonetics, Maintains $88 Price Target
📈 PositiveBarrington Research Maintains Outperform on Haemonetics, Raises Price Target to $90
📈 PositiveNeedham Maintains Buy on Haemonetics, Raises Price Target to $78
📈 PositiveBTIG Maintains Buy on Haemonetics, Raises Price Target to $88
📈 PositiveHaemonetics shares are trading higher after Q2 earnings beat estimates and the company raised FY2026 EPS guidance.
📈 PositiveUpdate: Haemonetics Raises FY2026 Adj EPS Guidance from $4.70-$5.00 to $4.80-$5.00 vs $4.83 Est; Raises FY2026 Sales Guidance from $1.230B-$1.270B to $1.257B-$1.296B vs $1.294B Est
📈 PositiveHaemonetics Raises FY2026 Adj EPS Guidance from $4.70-$5.00 to $4.80-$5.00 vs $4.83 Est
📈 PositiveHaemonetics Q2 Adj. EPS $1.27 Beats $1.11 Estimate, Sales $327.316M Beat $311.399M Estimate
📈 PositiveBarrington Research Maintains Outperform on Haemonetics, Maintains $86 Price Target
📈 PositiveCitigroup Maintains Buy on Haemonetics, Lowers Price Target to $64
➖ NeutralBarrington Research Maintains Outperform on Haemonetics, Maintains $86 Price Target
📈 PositiveFrequently Asked Questions about HAE
What is HAE's current stock price?
What is the analyst price target for HAE?
What sector is Haemonetics Corporation in?
What is HAE's market cap?
Does HAE pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HAE for comparison